No Picture
News

BioAtla Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ — BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer, today an… […]

No Picture
News

Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway

SAN MATEO, Calif., Dec. 16, 2020 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $30 million Series C fin… […]

No Picture
News

Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology

CARLSBAD, Calif., Dec. 15, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, today announced that the United States … […]

No Picture
News

Singlera Genomics raises $150 million in Series B financing to promote the development and commercialization of early cancer screening products

SAN DIEGO and SHANGHAI, Dec. 15, 2020 /PRNewswire/ — Singlera Genomics Inc. today announced that it raised $150 million in Series B financing. This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Cap… […]